Timothy Luxton1, Natalie King2, Christoph Wälti3, Lars Jeuken2,4, Jonathan Sandoe5. 1. School of Biomedical Sciences, University of Leeds, Leeds LS2 9JT, UK. 2. Leeds Institute of Health Sciences, University of Leeds, Leeds LS2 9JT, UK. 3. School of Electronic and Electrical Engineering, University of Leeds, Leeds LS2 9JT, UK. 4. Leiden Institute of Chemistry, Leiden University, PO Box 9502, 2300 RA, Leiden, The Netherlands. 5. School of Medicine, University of Leeds, Leeds LS2 9JT, UK.
Abstract
BACKGROUND: Dosing regimens guided by therapeutic drug monitoring (TDM) may be able to improve penicillin exposure in patients, which could result in improved patient health outcomes. OBJECTIVES: This systematic review aims to describe the impact penicillin TDM has on health outcomes, including antimicrobial resistance (AMR). METHODS: Studies measuring penicillins in patient samples that adjusted regimens according to the result, and reported health outcomes were selected. Study bias was assessed according to study type. Included study characteristics were tabulated and described by narrative synthesis. RESULTS: Three randomized controlled trials (RCTs), 16 cohort studies, and 9 case studies were included. No RCTs showed statistically significant improvements in health outcomes. Five cohort studies showed improvement in at least one health outcome associated with target attainment. However, there was a high risk of bias in all studies for health outcomes. One study assessed the impact of penicillin TDM on AMR and found that improved target attainment was associated with suppression of resistance. No studies found a detrimental effect of penicillin TDM. CONCLUSIONS: There is little evidence to suggest that TDM improves health outcomes, however neither health outcomes nor impact on AMR were adequately addressed. Variations in TDM implementation meant that a meta-analysis was not suitable. Penicillin TDM needs standardization, however there is currently no clear evidence of optimal conditions. Suitably powered studies are required to resolve the ambiguity surrounding the impact of TDM on clinical outcomes, including AMR. Further, standardized protocols and concentration targets need to be identified for TDM to be implemented successfully.
BACKGROUND: Dosing regimens guided by therapeutic drug monitoring (TDM) may be able to improve penicillin exposure in patients, which could result in improved patient health outcomes. OBJECTIVES: This systematic review aims to describe the impact penicillin TDM has on health outcomes, including antimicrobial resistance (AMR). METHODS: Studies measuring penicillins in patient samples that adjusted regimens according to the result, and reported health outcomes were selected. Study bias was assessed according to study type. Included study characteristics were tabulated and described by narrative synthesis. RESULTS: Three randomized controlled trials (RCTs), 16 cohort studies, and 9 case studies were included. No RCTs showed statistically significant improvements in health outcomes. Five cohort studies showed improvement in at least one health outcome associated with target attainment. However, there was a high risk of bias in all studies for health outcomes. One study assessed the impact of penicillin TDM on AMR and found that improved target attainment was associated with suppression of resistance. No studies found a detrimental effect of penicillin TDM. CONCLUSIONS: There is little evidence to suggest that TDM improves health outcomes, however neither health outcomes nor impact on AMR were adequately addressed. Variations in TDM implementation meant that a meta-analysis was not suitable. Penicillin TDM needs standardization, however there is currently no clear evidence of optimal conditions. Suitably powered studies are required to resolve the ambiguity surrounding the impact of TDM on clinical outcomes, including AMR. Further, standardized protocols and concentration targets need to be identified for TDM to be implemented successfully.
Authors: Laila S Al Yazidi; Sofia A Badran; Indy Sandaradura; Kevin Swil; Brendan McMullan Journal: J Paediatr Child Health Date: 2019-02 Impact factor: 1.954
Authors: Jan J De Waele; S Carrette; M Carlier; V Stove; J Boelens; G Claeys; I Leroux-Roels; E Hoste; P Depuydt; J Decruyenaere; A G Verstraete Journal: Intensive Care Med Date: 2013-12-20 Impact factor: 17.440
Authors: Daniel C Richter; Otto Frey; Anka Röhr; Jason A Roberts; Andreas Köberer; Thomas Fuchs; Nikolaos Papadimas; Monika Heinzel-Gutenbrunner; Thorsten Brenner; Christoph Lichtenstern; Markus A Weigand; Alexander Brinkmann Journal: Infection Date: 2019-08-31 Impact factor: 3.553
Authors: Isabelle K Delattre; Fabio S Taccone; Frédérique Jacobs; Maya Hites; Thierry Dugernier; Herbert Spapen; Pierre-François Laterre; Pierre E Wallemacq; Françoise Van Bambeke; Paul M Tulkens Journal: Expert Rev Anti Infect Ther Date: 2017-06-19 Impact factor: 5.091
Authors: Jason A Roberts; Mohd H Abdul-Aziz; Jeffrey Lipman; Johan W Mouton; Alexander A Vinks; Timothy W Felton; William W Hope; Andras Farkas; Michael N Neely; Jerome J Schentag; George Drusano; Otto R Frey; Ursula Theuretzbacher; Joseph L Kuti Journal: Lancet Infect Dis Date: 2014-04-24 Impact factor: 25.071
Authors: Stefan Hagel; Sandra Fiedler; Andreas Hohn; Alexander Brinkmann; Otto R Frey; Heike Hoyer; Peter Schlattmann; Michael Kiehntopf; Jason A Roberts; Mathias W Pletz Journal: Trials Date: 2019-06-06 Impact factor: 2.279
Authors: Ute Chiriac; Daniel C Richter; Otto R Frey; Anka C Röhr; Sophia Helbig; Judit Preisenberger; Stefan Hagel; Jason A Roberts; Markus A Weigand; Alexander Brinkmann Journal: Antibiotics (Basel) Date: 2021-06-03
Authors: Fekade Bruck Sime; Michael S Roberts; Sandra L Peake; Jeffrey Lipman; Jason A Roberts Journal: Ann Intensive Care Date: 2012-07-28 Impact factor: 6.925
Authors: G Macheda; N El Helali; G Péan de Ponfilly; M Kloeckner; P Garçon; M Maillet; V Tolsma; C Mory; A Le Monnier; B Pilmis Journal: Eur J Clin Microbiol Infect Dis Date: 2022-08-19 Impact factor: 5.103